Jaguar Health, Inc. (JAGX)Healthcare | Biotechnology | San Francisco, United States | NasdaqCM
0.41 USD
+0.01
(3.485%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:28 a.m. EDT
Sell signal due to negative directional forecast (-31.5%) and critical balance sheet risks despite near-term speculative hype; fundamental deterioration with deep losses, high debt, and revenue contraction makes it an avoidable trap. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.111933 |
| AutoARIMA | 0.114285 |
| MSTL | 0.405470 |
| AutoETS | 0.442969 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 58% |
| H-stat | 0.51 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 1.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 4.935 |
| Market Cap | 5,335,300 |
| Forward P/E | -0.07 |
| Beta | 0.29 |
| Website | https://jaguar.health |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.9327869 |
| Address1 | 200 Pine Street |
| Address2 | Suite 400 |
| All Time High | 2,501,887,490.0 |
| All Time Low | 0.313 |
| Ask | 0.5021 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 732,380 |
| Average Daily Volume3 Month | 625,896 |
| Average Volume | 625,896 |
| Average Volume10Days | 732,380 |
| Beta | 0.289 |
| Bid | 0.2814 |
| Bid Size | 2 |
| Book Value | -2.834 |
| City | San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.4098 |
| Current Ratio | 0.5 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.41 |
| Day Low | 0.3863 |
| Display Name | Jaguar Health |
| Dividend Date | 1,559,865,600 |
| Earnings Call Timestamp End | 1,775,824,200 |
| Earnings Call Timestamp Start | 1,775,824,200 |
| Earnings Timestamp | 1,775,565,000 |
| Earnings Timestamp End | 1,778,761,800 |
| Earnings Timestamp Start | 1,778,761,800 |
| Ebitda | -43,195,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.136 |
| Enterprise To Revenue | 4.262 |
| Enterprise Value | 49,060,300 |
| Eps Forward | -5.68 |
| Eps Trailing Twelve Months | -22.97 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.52458 |
| Fifty Day Average Change | -0.11478001 |
| Fifty Day Average Change Percent | -0.21880363 |
| Fifty Two Week Change Percent | -93.27869 |
| Fifty Two Week High | 15.48 |
| Fifty Two Week High Change | -15.0702 |
| Fifty Two Week High Change Percent | -0.97352713 |
| Fifty Two Week Low | 0.313 |
| Fifty Two Week Low Change | 0.0968 |
| Fifty Two Week Low Change Percent | 0.30926517 |
| Fifty Two Week Range | 0.313 - 15.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,431,437,400,000 |
| Float Shares | 12,089,831 |
| Forward Eps | -5.68 |
| Forward P E | -0.07214789 |
| Free Cashflow | -14,615,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 47 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.67213994 |
| Gross Profits | 7,737,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10343 |
| Held Percent Institutions | 0.00503 |
| Implied Shares Outstanding | 13,019,278 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,742,774,400 |
| Last Split Factor | 1:25 |
| Long Business Summary | Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. |
| Long Name | Jaguar Health, Inc. |
| Market | us_market |
| Market Cap | 5,335,300 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_12827020 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -53,575,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,296,241 |
| Number Of Analyst Opinions | 1 |
| Open | 0.4 |
| Operating Cashflow | -23,686,000 |
| Operating Margins | -6.31901 |
| Payout Ratio | 0.0 |
| Phone | 415 371 8300 |
| Pre Market Change | 0.0011000037 |
| Pre Market Change Percent | 0.27040407 |
| Pre Market Price | 0.4079 |
| Pre Market Time | 1,776,774,573 |
| Previous Close | 0.396 |
| Price Hint | 4 |
| Price To Book | -0.14460126 |
| Price To Sales Trailing12 Months | 0.4634958 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.066 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.013799995 |
| Regular Market Change Percent | 3.4848473 |
| Regular Market Day High | 0.41 |
| Regular Market Day Low | 0.3863 |
| Regular Market Day Range | 0.3863 - 0.41 |
| Regular Market Open | 0.4 |
| Regular Market Previous Close | 0.396 |
| Regular Market Price | 0.4098 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 253,438 |
| Return On Assets | -0.61456 |
| Revenue Growth | -0.078 |
| Revenue Per Share | 4.935 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 13,019,277 |
| Shares Percent Shares Out | 0.0388 |
| Shares Short | 481,255 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 327,563 |
| Short Name | Jaguar Health, Inc. |
| Short Percent Of Float | 0.0388 |
| Short Ratio | 1.01 |
| Source Interval | 15 |
| State | CA |
| Symbol | JAGX |
| Target High Price | 7.5 |
| Target Low Price | 7.5 |
| Target Mean Price | 7.5 |
| Target Median Price | 7.5 |
| Total Cash | 968,000 |
| Total Cash Per Share | 0.074 |
| Total Debt | 43,607,000 |
| Total Revenue | 11,511,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -22.97 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.404555 |
| Two Hundred Day Average Change | -0.99475497 |
| Two Hundred Day Average Change Percent | -0.70823497 |
| Type Disp | Equity |
| Volume | 253,438 |
| Website | https://jaguar.health |
| Zip | 94,104 |